Endometriosis (EMs) is a gynecological disorder characterized by chronic inflammation and an aberrant immune microenvironment. In this study, we integrated the GSE6364 dataset from the GEO database to identify differentially …
Endometriosis is a mysterious disease that affects 5 %-10 % of the women of reproductive age. Circular RNAs (circRNAs), a type of noncoding RNA, are involved in its progression, yet …
Endometriosis (EMs) with anxiety/depression is a common comorbidity of EMs, yet effective treatments are still lacking. Leaves of Paeonia suffruticosa Andr. (PSL) have potential therapeutic effects on EMs and their …
Endometriosis is characterized by the presence of endometrial tissue outside the uterine cavity. The administration of drugs designated for this condition has significant adverse effects, such as signs of estrogen …
This narrative review examines the therapeutic potential of Erastin and its derivatives for endometriosis (EMS) by integrating mechanistic, preclinical, and translational perspectives. We conducted a focused review of literature from …
Currently, CA125 combined with other biomarkers significantly outperforms CA125 alone in diagnosing endometriosis (EM), but the efficiency of combined diagnosis remains unclear. This network meta-analysis compared the accuracy of CA125 …
The goal was to develop a pragmatic classification system for conditions associated with chronic pelvic pain (CPP), aiming to enhance diagnosis, management, education, and research of CPP. An international, multidisciplinary …
Chinese patent medicines (CPMs), standardized herbal formulations widely used in clinical practice, combined with hormones have shown favorable therapeutic effects in the adjuvant treatment of endometriosis (EMS) after laparoscopic surgery. …
Decidualization is the transformation of endometrial stromal cells into functionally specialized cells during the early stages of pregnancy. Occurring in mammals that develop invasive hemochorial placentae, decidualization is a pivotal …
Triptorelin, a gonadotropin-releasing hormone(GnRH) agonist, is approved by the US Food and Drug Administration(FDA) for treating advanced prostate cancer, endometriosis, and central precocious puberty(CPP) in children aged ≥ 2 years. …